Description

AbbVie: Rinvoq & Skyrizi Are Powering a New Immunology Growth Engine—How Big Can This Duo Get?

AbbVie reported a strong third quarter for 2025, exceeding its financial guidance and maintaining momentum across its portfolio. The company saw adjusted earnings per share of $1.86, outperforming the previous forecast by $0.10, supported by a growth trajectory that led to a revenue of nearly $15.8 billion, surpassing expectations by approximately $300 million. Rob Michael, the Chairman and CEO, highlighted significant contributions from Skyrizi and Rinvoq, which collectively observed over 40% sales growth, establishing them as pivotal products in the immunology segment. Furthermore, neuroscience exhibited double-digit growth, making it the second largest therapeutic area for the company. The pipeline expansion is noteworthy, with Ashtravin-R&D expenses projected to rise to $9 billion, which is directed towards a diverse array of therapeutic areas including immunology, oncology, neuroscience, aesthetics, and obesity. Several products, such as tavapadon and PVEK, are slated for potential approvals, promising to further bolster growth in the coming years.